ADMA Biologics, Inc. is a late-stage biopharmaceutical company that develops, manufactures and intends to market specialty plasma-based biologics for the treatment and prevention of infectious diseases. The Company is engaged in the development and commercialization of human plasma and plasma-derived therapeutics. Its segments include Plasma Collection Centers, which includes its operations in Georgia; Research and Development, which includes its plasma development operations in New Jersey, and Corporate. Its targeted patient populations are immune-compromised individuals suffering from an underlying immune deficiency disorder or may be immune-suppressed for medical reasons. Its product candidates are intended to be used by physician specialists focused on caring for immune-compromised patients at risk of contracting infectious diseases. Its intravenous immunoglobulin product candidate, RI-002, is intended for the treatment of primary immune deficiency disease.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Bio Therapeutic Drugs
- Sub-Industry: N/A
- Symbol: NASDAQ:ADMA
- CUSIP: N/A
- Web: www.admabiologics.com
Capitalization:- Market Cap: $52.32 million
- Outstanding Shares: 12,886,000
Average Prices:- 50 Day Moving Avg: $3.79
- 200 Day Moving Avg: $4.62
- 52 Week Range: $2.93 - $8.00
P/E:- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: -4.14
- P/E Growth: 0.00
Sales & Book Value:- Annual Revenue: $11.17 million
- Price / Sales: 4.68
- Book Value: ($0.83) per share
- Price / Book: -4.89
Profitability:- EBIDTA: ($18,640,000.00)
- Net Margins: -191.99%
- Return on Equity: -6,405.90%
- Return on Assets: -85.33%
Debt:- Debt-to-Equity Ratio: -1.01%
- Current Ratio: 1.21%
- Quick Ratio: 0.80%
Misc:- Average Volume: 32,916 shs.
- Beta: 2.56
- Short Ratio: 2.26
Frequently Asked Questions for ADMA Biologics (NASDAQ:ADMA)
What is ADMA Biologics' stock symbol?
ADMA Biologics trades on the NASDAQ under the ticker symbol "ADMA."
How were ADMA Biologics' earnings last quarter?
ADMA Biologics Inc (NASDAQ:ADMA) announced its quarterly earnings results on Friday, May, 12th. The company reported ($0.51) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($0.28) by $0.23. The firm had revenue of $2.63 million for the quarter, compared to analyst estimates of $3.35 million. ADMA Biologics had a negative net margin of 191.99% and a negative return on equity of 6,405.90%. View ADMA Biologics' Earnings History.
When will ADMA Biologics make its next earnings announcement?
Where is ADMA Biologics' stock going? Where will ADMA Biologics' stock price be in 2017?
2 brokers have issued 1-year price objectives for ADMA Biologics' shares. Their predictions range from $13.00 to $13.00. On average, they anticipate ADMA Biologics' share price to reach $13.00 in the next year. View Analyst Ratings for ADMA Biologics.
Who are some of ADMA Biologics' key competitors?
Some companies that are related to ADMA Biologics include MaxCyte (MXCT), Pfenex (PFNX), Applied Genetic Technologies Corporation (AGTC), Zafgen (ZFGN), Ophthotech Corporation (OPHT), AcelRx Pharmaceuticals (ACRX), Affimed N.V. (AFMD), MEI Pharma (MEIP), Verastem (VSTM), Ergomed PLC (ERGO), Nexvet Biopharma PLC (NVET), Lipocine (LPCN), Rexahn Pharmaceuticals (RNN), Intec Pharma (NTEC), Synthetic Biologics (SYN), Galmed Pharmaceuticals (GLMD), Flex Pharma (FLKS) and ImmuPharma PLC (IMM).
Who are ADMA Biologics' key executives?
ADMA Biologics' management team includes the folowing people:
- Steven A. Elms, Chairman of the Board
- Adam S. Grossman, President, Chief Executive Officer, Director
- Jerrold B. Grossman D.P.S, Vice Chairman of the Board
- Brian Lenz, Chief Financial Officer
- James Mond M.D., Ph.D., Chief Scientific and Medical Officer
- Bernhard R. M. Ehmer, Director
- Bryant E. Fong, Independent Director
- Dov A. Goldstein M.D., Independent Director
- Lawrence P. Guiheen, Independent Director
- Eric I. Richman, Independent Director
Who owns ADMA Biologics stock?
ADMA Biologics' stock is owned by a number of of institutional and retail investors. Top institutional shareholders include
BIOTEST AG
(25.00%), Aisling Capital LLC (0.00%), Biomark Capital Management Co. LLC (0.00%), Broadfin Capital LLC (7.98%), Perceptive Advisors LLC (5.60%) and FMR LLC (0.00%). Company insiders that own ADMA Biologics stock include Adam S Grossman, Brian Lenz, James Mond and Jerrold B Grossman. View Institutional Ownership Trends for ADMA Biologics.
Who sold ADMA Biologics stock? Who is selling ADMA Biologics stock?
Who bought ADMA Biologics stock? Who is buying ADMA Biologics stock?
ADMA Biologics' stock was purchased by a variety of institutional investors in the last quarter, including Vanguard Group Inc. and Geode Capital Management LLC. Company insiders that have bought ADMA Biologics stock in the last two years include Adam S Grossman, Brian Lenz, James Mond and Jerrold B Grossman. View Insider Buying and Selling for ADMA Biologics.
How do I buy ADMA Biologics stock?
Shares of ADMA Biologics can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is ADMA Biologics' stock price today?
One share of ADMA Biologics stock can currently be purchased for approximately $4.06.
MarketBeat Community Rating for ADMA Biologics (NASDAQ ADMA)MarketBeat's community ratings are surveys of what our community members think about ADMA Biologics and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Consensus Ratings for ADMA Biologics (NASDAQ:ADMA) (How are Consensus Ratings Calculated?) MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
| Ratings Breakdown: | 1 Hold Rating, 1 Buy Rating |
| Consensus Rating: | Buy (Score: 2.50) |
| Consensus Price Target: | $13.00 (220.20% upside) |
Analysts' Ratings History for ADMA Biologics (NASDAQ:ADMA)
Show:
| Date | Firm | Action | Rating | Price Target | Impact on Share Price | Details |
|---|
| 6/7/2017 | Maxim Group | Set Price Target | Buy | $13.00 | Low |  |
| 8/1/2016 | Raymond James Financial, Inc. | Downgrade | Strong-Buy -> Market Perform | | N/A | |
(Data available from 6/27/2015 forward)
Earnings History for ADMA Biologics (NASDAQ:ADMA)Earnings History by Quarter for ADMA Biologics (NASDAQ ADMA)| Date | Quarter | Consensus Estimate | Actual EPS | Revenue Estimate | Actual Revenue | Release Link | Conference Call | Details |
|---|
| 8/10/2017 | | | | | | | | |
| 5/12/2017 | Q1 2017 | ($0.28) | ($0.51) | $3.35 million | $2.63 million | View | N/A | |
| 11/10/2016 | Q3 2016 | ($0.42) | ($0.34) | $2.32 million | $2.94 million | View | N/A | |
| 8/12/2016 | Q2 | ($0.39) | ($0.50) | $2.35 million | $2.27 million | View | N/A | |
| 5/13/2016 | Q1 | ($0.37) | ($0.43) | $2.48 million | $2.12 million | View | N/A | |
| 11/10/2015 | Q315 | ($0.39) | ($0.48) | $1.50 million | $1.85 million | View | N/A | |
| 8/11/2015 | Q215 | ($0.32) | ($0.37) | $1.50 million | $1.30 million | View | N/A | |
| 5/12/2015 | Q115 | ($0.32) | ($0.37) | $1.50 million | $1.50 million | View | N/A | |
| 3/9/2015 | Q4 2014 | ($0.38) | ($0.38) | $1.52 million | $1.41 million | View | N/A | |
| 11/10/2014 | Q3 2014 | ($0.37) | ($0.36) | | $1.37 million | View | N/A | |
(Data available from 1/1/2011 forward)
Earnings Estimates for ADMA Biologics (NASDAQ:ADMA)| Quarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
|---|
| Q2 2017 | 1 | ($0.30) | ($0.30) | ($0.30) |
| Q3 2017 | 1 | ($0.15) | ($0.15) | ($0.15) |
| Q4 2017 | 1 | ($0.14) | ($0.14) | ($0.14) |
(Data provided by Zacks Investment Research)
Dividend History for ADMA Biologics (NASDAQ:ADMA)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for ADMA Biologics (NASDAQ:ADMA)Insider Ownership Percentage: 60.44%
Institutional Ownership Percentage: 71.65%
Insider Trades by Quarter for ADMA Biologics (NASDAQ:ADMA)| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Details |
|---|
| 5/3/2016 | Adam S Grossman | CEO | Buy | 200,000 | $6.50 | $1,300,000.00 | |
| 5/3/2016 | Brian Lenz | CFO | Buy | 2,500 | $6.50 | $16,250.00 | |
| 5/3/2016 | James Mond | CMO | Buy | 770 | $6.50 | $5,005.00 | |
| 5/3/2016 | Jerrold B Grossman | Director | Buy | 45,769 | $6.50 | $297,498.50 | |
| 12/8/2015 | Adam S. Grossman | CEO | Buy | 500 | $9.00 | $4,500.00 | |
| 12/7/2015 | Jerrold B Grossman | Director | Buy | 500 | $9.01 | $4,505.00 | |
| 12/2/2015 | Adam S Grossman | CEO | Buy | 2,250 | $9.15 | $20,587.50 | |
| 12/2/2015 | Brian Lenz | CFO | Buy | 1,000 | $9.15 | $9,150.00 | |
| 12/2/2015 | Jerrold B Grossman | Director | Buy | 6,000 | $9.16 | $54,960.00 | |
| 12/1/2015 | Adam S Grossman | CEO | Buy | 1,800 | $9.17 | $16,506.00 | |
| 11/25/2015 | Adam S Grossman | CEO | Buy | 1,800 | $9.18 | $16,524.00 | |
| 11/20/2015 | Adam S Grossman | CEO | Buy | 3,861 | $9.21 | $35,559.81 | |
| 3/19/2015 | Adam S Grossman | CEO | Buy | 2,000 | $8.50 | $17,000.00 | |
| 3/17/2015 | Adam S Grossman | CEO | Buy | 5,500 | $7.98 | $43,890.00 | |
| 3/17/2015 | Jerrold B Grossman | Director | Buy | 500 | $8.01 | $4,005.00 | |
| 3/16/2015 | Adam S Grossman | CEO | Buy | 8,800 | $8.03 | $70,664.00 | |
| 3/16/2015 | James Mond | CMO | Buy | 1,250 | $8.02 | $10,025.00 | |
| 3/16/2015 | Lawrence P Guiheen | Director | Buy | 1,000 | $7.96 | $7,960.00 | |
| 3/13/2015 | Eric I Richman | Director | Buy | 3,500 | $7.88 | $27,580.00 | |
| 9/12/2014 | Adam S Grossman | CEO | Buy | 4,300 | $9.57 | $41,151.00 | |
| 8/22/2014 | Adam S Grossman | CEO | Buy | 1,000 | $9.50 | $9,500.00 | |
| 8/14/2014 | Adam S Grossman | CEO | Buy | 2,100 | $9.77 | $20,517.00 | |
| 6/18/2014 | Adam S Grossman | CEO | Buy | 1,875 | $9.59 | $17,981.25 | |
| 5/22/2014 | Adam S Grossman | CEO | Buy | 4,226 | $8.15 | $34,441.90 | |
| 5/15/2014 | Adam S Grossman | CEO | Buy | 13,400 | $7.50 | $100,500.00 | |
| 5/14/2014 | Brian Lenz | CFO | Buy | 1,000 | $7.50 | $7,500.00 | |
| 5/14/2014 | James Mond | CMO | Buy | 1,315 | $7.60 | $9,994.00 | |
| 12/10/2013 | Jerrold B Grossman | Director | Buy | 3,650 | $7.30 | $26,645.00 | |
(Data available from 1/1/2013 forward)
Headline Trends for ADMA Biologics (NASDAQ:ADMA)
Latest Headlines for ADMA Biologics (NASDAQ:ADMA)
| Source: |
|
| Date | Headline |
|---|
 | ADMA Biologics Provides Corporate Timeline and Activities Update to Stockholders
finance.yahoo.com - June 27 at 3:24 PM |
 | BRIEF-Adma Biologics says approved 5 pct increases in annual cash bonuses to CEO, CFO among others
www.reuters.com - June 9 at 8:26 PM |
 | ADMA Biologics (ADMA) Presents At Jefferies 2017 Global Healthcare Conference - Slideshow
seekingalpha.com - June 8 at 8:26 PM |
 | Zacks: ADMA Biologics Inc (ADMA) Given $10.50 Average Target Price by Brokerages
www.americanbankingnews.com - June 8 at 8:50 AM |
| ADMA Biologics Inc (ADMA) Given a $13.00 Price Target by Maxim Group Analysts
www.americanbankingnews.com - June 7 at 7:18 PM |
| BRIEF-Biotest sells US therapy business to Adma Biologics, Inc.
www.reuters.com - June 7 at 3:24 PM |
| ADMA Biologics Completes Acquisition of Biotest’s Therapy Business Unit Assets
finance.yahoo.com - June 6 at 8:33 PM |
| ETFs with exposure to ADMA Biologics, Inc. : June 5, 2017
finance.yahoo.com - June 5 at 6:41 PM |
| Zacks: Brokerages Anticipate ADMA Biologics Inc (ADMA) Will Announce Quarterly Sales of $3.32 Million
www.americanbankingnews.com - June 4 at 7:54 AM |
| ADMA Biologics Inc (ADMA) Expected to Post Earnings of -$0.30 Per Share
www.americanbankingnews.com - June 2 at 6:24 PM |
| ADMA Biologics, Inc. :ADMA-US: Earnings Analysis: Q1, 2017 By the Numbers : June 2, 2017
finance.yahoo.com - June 2 at 4:15 PM |
| ADMA Biologics to Present at Jefferies 2017 Healthcare Conference
finance.yahoo.com - May 25 at 8:38 PM |
| ADMA: 1Q:17 Results and Biotest Acquisition: Valuation Implications
finance.yahoo.com - May 19 at 8:19 PM |
| ADMA Biologics Inc to Post Q2 2017 Earnings of ($0.30) Per Share, Zacks Investment Research Forecasts (ADMA)
www.americanbankingnews.com - May 18 at 8:42 AM |
| ADMA Biologics Inc (ADMA) Announces Earnings Results
www.americanbankingnews.com - May 15 at 10:58 AM |
| BRIEF-ADMA Biologics Q1 loss per share $0.51
www.reuters.com - May 13 at 3:23 PM |
| ADMA Biologics Provides Corporate Update and Reports First Quarter 2017 Financial Results
finance.yahoo.com - May 12 at 8:54 PM |
| Adma Biologics reports 1Q loss
finance.yahoo.com - May 12 at 8:54 PM |
| ADMA Biologics Inc (ADMA) to Release Quarterly Earnings on Thursday
www.americanbankingnews.com - May 9 at 7:00 AM |
| ADMA Biologics (ADMA) Receiving Positive News Coverage, Report Finds
www.americanbankingnews.com - May 4 at 7:54 AM |
| ADMA Biologics (ADMA) Earns Daily News Sentiment Rating of 0.37
www.americanbankingnews.com - April 26 at 2:08 PM |
| ADMA Biologics (ADMA) Receiving Very Positive Press Coverage, AlphaOne Reports
www.americanbankingnews.com - April 23 at 7:38 AM |
| ETFs with exposure to ADMA Biologics, Inc. : April 20, 2017
finance.yahoo.com - April 20 at 3:21 PM |
| ADMA Biologics (ADMA) Receives Coverage Optimism Rating of 0.33
www.americanbankingnews.com - April 15 at 8:46 AM |
| ETFs with exposure to ADMA Biologics, Inc. : April 7, 2017
finance.yahoo.com - April 7 at 8:21 PM |
| Short Interest in ADMA Biologics Inc (ADMA) Rises By 13.6%
www.americanbankingnews.com - April 6 at 11:51 AM |
 | Biotest AG: Discussions regarding possible business combination
uk.finance.yahoo.com - March 29 at 8:27 PM |
 | Shareholder Alert: Monteverde & Associates PC Announces An Investigation Of ADMA Biologics, Inc. - ADMA - PR Newswire (press release)
www.prnewswire.com - March 28 at 8:02 AM |
| Shareholder Alert: Monteverde & Associates PC Announces An Investigation Of ADMA Biologics, Inc. - ADMA
finance.yahoo.com - March 28 at 8:02 AM |
| ADMA BIOLOGICS, INC. Financials
finance.yahoo.com - March 2 at 3:30 PM |
| ADMA BIOLOGICS, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhi
biz.yahoo.com - February 24 at 6:19 PM |
| ADMA Biologics Reports Year End 2016 Financial Results, Accomplishments and Upcoming Milestones
finance.yahoo.com - February 24 at 6:19 PM |
| ADMA BIOLOGICS, INC. Files SEC form 8-K, Change in Directors or Principal Officers
biz.yahoo.com - February 18 at 7:49 AM |
 | Form 4 ADMA BIOLOGICS, INC. For: Feb 14 Filed by: LENZ BRIAN - StreetInsider.com
www.streetinsider.com - February 17 at 9:41 AM |
| Form 4 ADMA BIOLOGICS, INC. For: Feb 14 Filed by: Guiheen Lawrence P. - StreetInsider.com
www.streetinsider.com - February 17 at 9:41 AM |
| Blood Plasma Market 2017-2021 Key Regions Competitive Analysis
www.prnewswire.com - January 27 at 9:45 PM |
| ADMA Biologics (ADMA) to Acquire Assets from Biotest Pharmaceuticals
www.streetinsider.com - January 25 at 1:43 AM |
 | DGAP-Adhoc: Biotest AG: Biotest verkauft US-Therapiegeschäft an ... - FinanzNachrichten.de
www.finanznachrichten.de - January 24 at 1:25 AM |
| ADMA Biologics upgraded by Maxim Group
finance.yahoo.com - January 23 at 8:24 PM |
| ADMA BIOLOGICS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Unregistered Sale of Equity Secu
biz.yahoo.com - January 23 at 8:24 PM |
ADMA Biologics (ADMA) Chart for Tuesday, June, 27, 2017
